Literature DB >> 33289891

lamassemble: Multiple Alignment and Consensus Sequence of Long Reads.

Martin C Frith1,2,3, Satomi Mitsuhashi4,5, Kazutaka Katoh6,7.   

Abstract

Long DNA and RNA reads from nanopore and PacBio technologies have many applications, but the raw reads have a substantial error rate. More accurate sequences can be obtained by merging multiple reads from overlapping parts of the same sequence. lamassemble aligns up to ∼1000 reads to each other, and makes a consensus sequence, which is often much more accurate than the raw reads. It is useful for studying a region of interest such as an expanded tandem repeat or other disease-causing mutation.

Keywords:  Dotplot; Genomic variations; LAST; MAFFT; Nanopore; PacBio; Paralogy; Repeat expansion disease; Strand-asymmetric error pattern; last-train

Mesh:

Year:  2021        PMID: 33289891     DOI: 10.1007/978-1-0716-1036-7_9

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  1 in total

1.  Training alignment parameters for arbitrary sequencers with LAST-TRAIN.

Authors:  Michiaki Hamada; Yukiteru Ono; Kiyoshi Asai; Martin C Frith
Journal:  Bioinformatics       Date:  2017-03-15       Impact factor: 6.937

  1 in total
  3 in total

1.  Genome-wide survey of tandem repeats by nanopore sequencing shows that disease-associated repeats are more polymorphic in the general population.

Authors:  Satomi Mitsuhashi; Martin C Frith; Naomichi Matsumoto
Journal:  BMC Med Genomics       Date:  2021-01-07       Impact factor: 3.063

2.  Updated HIV-1 Consensus Sequences Change but Stay Within Similar Distance From Worldwide Samples.

Authors:  Gregorio V Linchangco; Brian Foley; Thomas Leitner
Journal:  Front Microbiol       Date:  2022-01-31       Impact factor: 6.064

3.  Nanopore direct RNA sequencing detects DUX4-activated repeats and isoforms in human muscle cells.

Authors:  Satomi Mitsuhashi; So Nakagawa; Mitsuru Sasaki-Honda; Hidetoshi Sakurai; Martin C Frith; Hiroaki Mitsuhashi
Journal:  Hum Mol Genet       Date:  2021-05-12       Impact factor: 6.150

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.